Table 1.
Clinical and genetic characteristics of patients after clustering.
| GBM | LGG | TOTAL | ||||
|---|---|---|---|---|---|---|
| Cluster1 | Cluster2 | Cluster1 | Cluster2 | Cluster1 | Cluster2 | |
| (N=146) | (N=7) | (N=104) | (N=426) | (N=250) | (N=433) | |
| Gender | ||||||
| Female | 60 (41%) | 1 (14%) | 45 (4%) | 163 (38%) | 105 (42%) | 164 (38%) |
| Male | 80 (55%) | 5 (71%) | 49 (47%) | 211 (50%) | 129 (52%) | 216 (50%) |
| Missing | 6 (4.1%) | 1 (14.3%) | 10 (9.6%) | 52 (12.2%) | 16 (6.4%) | 53 (12.2%) |
| Age (years) | ||||||
| <52 | 31 (21%) | 5 (71%) | 42 (40%) | 292 (69%) | 73 (29%) | 297 (69%) |
| >66 | 48 (33%) | 0 (0%) | 14 (13%) | 17 (4%) | 62 (25%) | 17 (4%) |
| 52–66 | 61 (42%) | 1 (14%) | 38 (37%) | 65 (15%) | 99 (40%) | 66 (15%) |
| Missing | 6 (4.1%) | 1 (14.3%) | 10 (9.6%) | 52 (12.2%) | 16 (6.4%) | 53 (12.2%) |
| IDH | ||||||
| Mutant | 2 (1%) | 7 (100%) | 8 (8%) | 423 (99%) | 10 (4%) | 430 (99%) |
| WT | 135 (92%) | 0 (0%) | 96 (92%) | 0 (0%) | 231 (92%) | 0 (0%) |
| Missing | 9 (6.2%) | 0 (0%) | 0 (0%) | 3 (0.7%) | 9 (3.6%) | 3 (0.7%) |
| pq | ||||||
| Codel | 0 (0%) | 0 (0%) | 1 (1%) | 171 (40%) | 1 (0%) | 171 (39%) |
| Non-codel | 143 (98%) | 7 (100%) | 103 (99%) | 255 (60%) | 246 (98%) | 262 (61%) |
| Missing | 3 (2.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (1.2%) | 0 (0%) |
| MGMT | ||||||
| Methylated | 56 (38%) | 6 (86%) | 40 (38%) | 397 (93%) | 96 (38%) | 403 (93%) |
| Unmethylated | 79 (54%) | 0 (0%) | 64 (62%) | 29 (7%) | 143 (57%) | 29 (7%) |
| Missing | 11 (7.5%) | 1 (14.3%) | 0 (0%) | 0 (0%) | 11 (4.4%) | 1 (0.2%) |
| Radiation therapy | ||||||
| Yes | 108 (74%) | 7 (100%) | 70 (67%) | 226 (53%) | 178 (71%) | 233 (54%) |
| No | 17 (12%) | 0 (0%) | 21 (20%) | 164 (38%) | 38 (15%) | 164 (38%) |
| Missing | 21 (14.4%) | 0 (0%) | 13 (12.5%) | 35 (8.2%) | 34 (13.6%) | 35 (8.1%) |